How much funding has Casma raised?

Casma has raised $154.5M in total funding, most recently a Series C round.

Who are Casma's investors?

Casma's investors include Third Rock Ventures, The Column Group, Amgen, Astellas Venture Management, Eventide Asset Management, Schroder Adveq.

Where is Casma headquartered?

Casma is headquartered in Cambridge, Massachusetts, United States.

What industry is Casma in?

Casma operates in Biotech, Healthcare.

Casma

Reprogramming autophagy to eliminate diseases that current drugs have failed to target

Cambridge, United States · Founded 2018 · $154.5M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2018
Business Model: B2B

Total Funding: $154.5M
Last Round: $46.0M Series CNov 2022
Rounds: 3

About

Casma Therapeutics is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, focused on harnessing the biology of autophagy and the lysosomal system to develop transformative therapies for diseases that have resisted conventional drug approaches. The company's proprietary PHLYT (Phagosome-Lysosome Targeting) platform enables the selective autophagy-mediated degradation of large and structurally complex disease targets — including organelles, protein aggregates, and signaling complexes — that are inaccessible to small-molecule or antibody-based drugs. Casma's lead clinical program, CSM-101, is a brain-penetrant small-molecule TRPML1 agonist designed to restore lysosomal function and has been nominated as a development candidate for the treatment of both rare and common forms of Parkinson's disease, including GBA-associated Parkinson's and idiopathic Parkinson's disease. The company received grant funding from The Michael J. Fox Foundation for Parkinson's Research to support IND-enabling studies for CSM-101. Casma has raised multiple rounds of venture financing including a $46 million Series C in November 2022, and continues to advance its pipeline across neurodegeneration, oncology, inflammation, and metabolic disorders.

Summary

Casma is a Biotech company based in Cambridge, United States, founded in 2018. It has raised $154.5M in total across 3 rounds, most recently a $46.0M Series C round in Nov 2022. Investors include Third Rock Ventures, The Column Group and Amgen.